Table 1:

Enrichment of human neurological gene sets

Source	Neurological Disorders gene set (previously published)	Size	Function/Description	Significant change in the expression of the gene set	Significance level
GSE12457	ADHD_down	32	Down-regulated genes by molecular alterations in genetic and environmental rat models of ADHD	Down-regulated	P-value = 0.000 Q-value = 0.003
GSE12457	ADHD_up	44	Up-regulated genes by molecular alterations in genetic and environmental rat models of ADHD	Down-regulated	P-value = 0.007 Q-value = 0.022
GSE1297	Alzheimers	308	Genes upregulated in the CA1 region of the hippocampus in Alzheimer’s disease	Up-regulated	P-value = 0.004 Q-value = 0.027
	Autism_idiopathic	439	Combination of Chakrabarti, Hu and ASD_2class; excluding duplicates	Up-regulated	P-value = 0.000 Q-value = 0.001
	Parkinsons	130	Genes associated with Parkinsons	Down-regulated	P-value = 0.000 Q-value = 0.000
	Schizophrenia	29	Differentially expressed proteins in the brains of SCZ patients	Down-regulated	P-value = 0.000 Q-value = 0.000
GSE15402	ASD_2Class	354	Differentially expressed genes (significantly) from a SAM 2-class analysis of the data from combined autistic samples and neurotypical controls	Up-regulated	P-value = 0.000 Q-value = 0.000
GSE15402	ASD_Mild	306	Differentially expressed genes (significantly) from a SAM 2-class analysis of the data from mild autistic samples and neurotypical controls	Up-regulated	P-value = 0.000 Q-value = 0.000

The table represents the analyses of gene sets associated with neurological disorders. Source indicates the database from where the gene set was derived, Gene Ontology (GO) or Molecular Signatures Database (MSigDB). Size represents the number of genes in each gene set. Significant change indicates the expression of gene sets which were significantly found up-regulated and down-regulated in the mixture treatment of pharmaceuticals on cultured human neuronal cells. Gene sets with P-value < 0.01 and Q-value < 0.1 were considered as statistically significantly enriched.